Search Results - "Mjörnstedt, L"

Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation by Mjörnstedt, L., Sørensen, S. S., von zur Mühlen, B., Jespersen, B., Hansen, J. M., Bistrup, C., Andersson, H., Gustafsson, B., Undset, L.H., Fagertun, H., Solbu, D., Holdaas, H.

“…In an open‐label, multicenter trial, de novo kidney transplant recipients at low to medium immunological risk were randomized at week 7 posttransplant to…”
Get full text

Successful Combined Partial Auxiliary Liver and Kidney Transplantation in Highly Sensitized Cross‐Match Positive Recipients by Olausson, M., Mjörnstedt, L., Nordén, G., Rydberg, L., Mölne, J., Bäckman, L., Friman, S.

“…Combined liver and renal transplantations can be performed against a positive cross‐match, indicating that the liver protects the kidney from the harmful HLA…”
Get full text

Mycophenolate mofetil in renal transplantation : 3-year results from the placebo-controlled trial by Vanrenterghem, Y

“…The European double-blind, placebo-(PLA) controlled study of mycophenolate mofetil (MMF) for prevention of acute renal allograft rejection showed that MMF 2…”
Get full text

Pseudoaneurysm of the Hepatic Artery Following Liver Transplantation by Fistouris, J., Herlenius, G., Bäckman, L., Olausson, M., Rizell, M., Mjörnstedt, L., Friman, S.

“…We report 12 cases of pseudoaneurysm hepatic artery (PA) among 825 liver transplantations (OLT) performed between January 1985 and December 2005. In the early…”
Get full text

Attenuation of Torque teno viral load over time in kidney transplantation recipients treated with calcineurin inhibitors is mitigated after conversion to belatacept by Bredewold, O. W., Moest, W. T., Fijter, J. W., Meijers, E., Bruchfeld, A., Skov, K., Svensson, M. H. S., Chan, J., Mjornstedt, L., Sorensen, S. S., Fellstrom, B., Feltkamp, M. C. W., Zonneveld, A. J., Rotmans, J. I.

“…Torque Teno Virus (TTV) is a non‐pathogenic anellovirus, highly prevalent in healthy populations. Variations in its viral load have been associated with states…”
Get full text

Successful ABO-incompatible liver transplantation using A2 donors by Skogsberg, U, Breimer, M E, Friman, S, Mjörnstedt, L, Mölne, J, Olausson, M, Rydberg, L, Svalander, C T, Bäckman, L

“…The longer waiting time for a liver graft among patients with blood group O makes it necessary to expand the donor pool for these patients. We herein have…”
Get full text

Kidney transplantation--a 46-year experience from the Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden by Friman, S, Nordén, G, Lennerling, A, Fehrman-Ekholm, I, Felldin, M, Hansson, S, Rydberg, L, Holgersson, J, Rizell, M, Kvarnström, N, Gustafsson, B, Gäbel, M, Olausson, M, Mjörnstedt, L

“…The limiting factor in organ transplantation is the availability of organs. Ongoing work to improve donation rates both at the public and the organizational…”
Get more information

Increase in Organ Donation Rate in a Swedish Region After Implementing a New Angle of Approach by Gustafsson, B.I., Wolfbrandt, A., Dahlman, S., Mjörnstedt, L.

“…In the Swedish Västra Götaland region (1.65 million inhabitants), we have implemented, as from January 1, 2006, a new concept to improve the organ donation…”
Get full text

Successful Treatment of Severe ABO Antibody-Mediated Rejection Using Bortezomib: A Case Report by Westphal, S, Hansson, S, Stelin, G, Holgersson, J, Mjörnstedt, L, Friman, S

“…Abstract Background Our program for ABO-incompatible renal transplantation includes antigen-specific immunoadsorption (extracorporeal columns with the A or B…”
Get full text

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study by Holdaas, H., Bentdal, Ø., Pfeffer, P., Mjørnstedt, L., Solbu, D., Midtvedt, K.

“…:  In a single‐center study, 20 kidney transplant patients without prior rejection were abruptly converted from cyclosporine to everolimus at seven wk…”
Get full text

What Are We Waiting For? Analyses of Factors Influencing Cold Ischemia Time by Wolfbrandt, A, Lindström, K, Mjörnstedt, L, Friman, S

“…Abstract Introduction Cold ischemia time (CIT) influences long-term graft survival after deceased donor (DD) kidney transplantation. The aim of the present…”
Get full text

Initial experience with multivisceral, cluster, and combined liver and small bowel transplantation in Sweden by Herlenius, G., Friman, S., Bäckman, L., Krantz, M., Saalman, R., Ascher, H., Nilsson, O., Mjörnstedt, L., Östraat, Ö.., Lindner, P., Cahlin, C., Gustafson, B., Rizell, M., Wramner, L., Olausson, M.

Get full text

Characterization of Forssman and Other Antigen/Antibody Systems in Vascularized Mouse Heart to Rat Xenotransplantation by Gustavsson, M. L., Johnsson, C., Albertsson, P., Lukes, D., Steen, L. M., Johansson, B. R., Mjörnstedt, L., Norrby, J., Tufveson, G., Olausson, M.

“…In the present study, the nature of hyperacute xenograft rejection was closely studied in a vascularized mouse‐to‐rat transplantation model. Antibodies against…”
Get full text

Is Rituximab Safe to Use in Kidney Transplant Patients? by Tydén, G., Mjornstedt, L., Ekberg, H., Tufveson, G.

Get full text

Early Recurrence of Nephrotic Syndrome (Immunoglobulin M Nephropathy) After Renal Transplantation Successfully Treated With Combinations of Plasma Exchanges, Immunoglobulin, and Rituximab by Westphal, S., Hansson, S., Mjörnstedt, L., Mölne, J., Swerkersson, S., Friman, S.

“…In contrast to focal segmental glomerulosclerosis, which is well known to recur early in a renal graft, there are only few cases described with recurrence of…”
Get full text

Antithymocyte Globulin and Cyclosporin A are Synergistic in an Experimental Transplantation Tolerance Model in the Rat by Olausson, M, Lukes, D, Norrby, J, Qi, Z, Ekberg, H, Gannedahl, G, Tufveson, G, Mjörnstedt, L

“…The aim of the present investigation was to study the possible synergistic effect between cyclosporin A (CsA) and antithymocyte globulin (ATG), using the…”
Get full text

Late Mortality in 679 Consecutive Liver Transplant Recipients: The Gothenburg Liver Transplant Experience by Lukes, D.J., Herlenius, G., Rizell, M., Mjörnstedt, L., Bäcman, L., Olausson, M., Friman, S.

“…Liver transplantation (OLT) is an established treatment with excellent early outcome. However, the long-term results are hampered by side effects of…”
Get full text

Alterations of the post transplant blood lymphocyte phenotype subsets as a marker of rejection in renal allograft recipients by Wramner, L, Mjörnstedt, L, Blohmé, I, Tufveson, G, Söderström, T, Olausson, M

“…The postoperative alterations of absolute levels of lymphocyte phenotype subsets in peripheral blood were studied in recipients of living donor renal…”
Get more information

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial by Bredewold, Obbo W., Chan, Joe, Svensson, My, Bruchfeld, Annette, de Fijter, Johan W., Furuland, Hans, Grinyo, Josep M., Hartmann, Anders, Holdaas, Hallvard, Hellberg, Olof, Jardine, Alan, Mjörnstedt, Lars, Skov, Karin, Smerud, Knut T., Soveri, Inga, Sørensen, Søren S., Zonneveld, Anton-Jan van, Fellström, Bengt

“…In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors…”
Get full text

Cell-mediated immune responses in renal transplant recipients treated with cyclosporin and prednisolone with or without azathioprine by Wramner, L, Mjörnstedt, L, Rydberg, L, Olausson, M

“…The cell-mediated immune response was studied, using mixed lymphocyte reactivity (MLR) and cell-mediated lympholysis (CML) tests, in patients with…”
Get more information